Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 106

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 106
---
 of the date of this prospectus, (i) all of the Private Placement Warrants and Public Warrants, which have an exercise price of $1,150.00 per share, (ii) all of the Rollover Warrants, which have an exercise price of $1,000.00 per share, and (iii) all of the Series A Common Warrants, which have a current exercise price of $139.00 per share, are “out of the money,” meaning the exercise price is higher than the market price of our Common Stock. Holders of such “out of the money” Warrants are not likely to exercise such Warrants. There can be no assurance that such Warrants will be in the money prior to their respective expiration dates, and therefore, we may not receive any cash proceeds from the exercise of such Warrants. An active trading market for our Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our Common Stock may be extremely volatile, and stockholders could lose all or part of their investment. The trading price of our Common Stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this “ Risk Factors” section and elsewhere in this prospectus, these factors include:

| ● | the commencement, enrollment or results of any planned and future preclinical studies and clinical trials of our product candidates or changes in the development status of our product candidates; |

57

| ● | any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings; |

| ● | adverse results from or delays in preclinical studies and clinical trials of our product candidates, including as a result of clinical holds, safety events, enrollment difficulties, or study protocol amendments; |

| ● | our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions, including failure to receive regulatory approval of our drug to market for our product candidates; |

| ● | adverse developments concerning our manufacturers; |

| ● | our inability to obtain adequate product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish collaborations, if needed; |

| ● | our failure to commercialize our product candidates; |

| ● | additions or